Portage Biotech (NASDAQ:PRTG) Trading Up 2.3%

Portage Biotech Inc. (NASDAQ:PRTG) shares were up 2.3% during trading on Thursday . The stock traded as high as $0.23 and last traded at $0.23. Approximately 121,091 shares were traded during mid-day trading, a decline of 43% from the average daily volume of 210,871 shares. The stock had previously closed at $0.22.

Portage Biotech Stock Performance

The firm’s fifty day simple moving average is $0.27 and its 200 day simple moving average is $0.62. The company has a market capitalization of $3.78 million, a price-to-earnings ratio of -0.03 and a beta of 1.61. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.78 and a quick ratio of 2.78.

Institutional Trading of Portage Biotech

A hedge fund recently bought a new stake in Portage Biotech stock. Armistice Capital LLC bought a new stake in shares of Portage Biotech Inc. (NASDAQ:PRTG) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 1,968,105 shares of the company’s stock, valued at approximately $4,113,000. Armistice Capital LLC owned about 11.06% of Portage Biotech at the end of the most recent reporting period. 13.36% of the stock is currently owned by institutional investors.

About Portage Biotech

Portage Biotech Inc, a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials.